# Utility of Transdermal Optical Imaging (TOI) as a Non-invasive Measure of Hydration Status: Phase 3a for Model Development

> **NCT06044610** · NA · COMPLETED · sponsor: **PepsiCo Global R&D** · enrollment: 32 (actual)

## Conditions studied

- Dehydration

## Interventions

- **OTHER:** GENPOP Passive dehydration (75% reduction in fluid intake
- **OTHER:** GENPOP Ad lib fluid intake
- **OTHER:** EXERCISE without fluid replacement
- **OTHER:** EXERCISE with fluid replacement

## Key facts

- **NCT ID:** NCT06044610
- **Lead sponsor:** PepsiCo Global R&D
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-08
- **Primary completion:** 2023-11-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044610, "Utility of Transdermal Optical Imaging (TOI) as a Non-invasive Measure of Hydration Status: Phase 3a for Model Development". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06044610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*